| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.32 | 1e-05 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0007 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.099 | 0.002 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.21 | 0.003 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.088 | 0.005 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.006 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.17 | 0.009 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | isoliquiritigenin | CTRPv2 | pan-cancer | AAC | 0.16 | 0.01 |